Bexmarilimab

Clevegen

Near Add Your Location

Accepting patients

BEXMAB

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
Learn more
  • BCL-2 Inhibitor
  • Monoclonal Antibody
  • Clever-1
  • Phase 1/2
  • Has results